mSEPT9 biomarker successfully validated as the first biomarker in blood capable of detecting previously unsuspected colorectal cancers in prospective colorectal cancer screening study
Final data to be submitted for publication in top-tier journal
The CE marked Epi proColon assay, based on mSEPT9, provides attractive and convenient alternative for colorectal cancer screening
Press release, Berlin, Germany, and Seattle, WA, USA |
